Jerusalem, Israel, December 5, 2000 - Teva Pharmaceutical Industries, Ltd., (Nasdaq: TEVA) announced today that Copaxone® was launched in the U.K., the product's first major European market.
Copaxone® (glatiramer acetate for injection) is indicated for reduction in frequency of relapses in relapsing-remitting multiple sclerosis (RR-MS). There are approximately 85,000 patients in the U.K of which 30,000 are RR-MS patients.
Copaxone® will be jointly marketed in the U.K. by Teva and Aventis.
Peter Cardy, Chief Executive of the U.K. MS Society said: "The MS Society welcomes the availability of another therapy which can improve the quality of life for many people with MS".
Recent published results of a six-year follow-up trial with Copaxone® - the only organized MS therapeutic trial ever to be maintained for such a long duration in RR-MS patients - demonstrated a sustained clinical benefit and its safety profile.
Copaxone® has been approved for marketing in 19 countries including the U.S., Israel, Canada, Australia and Switzerland and has been used worldwide in over 30,000 patients.
In the U.S., the major market of the product, Copaxone® is the fastest growing multiple sclerosis therapy, outpacing the overall MS drug market with a market share exceeding 25%.
Teva Pharmaceutical Industries Ltd., headquartered in Israel, is among the top 50 pharmaceutical companies and among the largest generic pharmaceutical companies in the world. Over 80% of its sales are outside Israel, mainly in North America and Europe. The Company develops, manufactures and markets generic and branded pharmaceuticals and active pharmaceutical ingredients.
Safe Harbor Statement under the U. S. Private Securities Litigation Reform Act of 1995: This release contains forward-looking statements, which express the current beliefs and expectations of management. Such statements are based on current expectations and involve a number of known and unknown risks and uncertainties that could cause Teva's future results, performance or achievements to differ significantly from the results, performance or achievements expressed or implied by such forward-looking statements. Important factors that could cause or contribute to such differences include Teva's ability to successfully develop and commercialize additional pharmaceutical products, the introduction of competitive generic products, the impact of competition from brand-name companies that sell their own generic products or successfully extend the exclusivity period of their branded products, Teva's ability to rapidly integrate the operations of acquired businesses, the availability of product liability coverage in the current insurance market, the impact of pharmaceutical industry regulation and pending legislation that could affect the pharmaceutical industry, the difficulty of predicting U.S. Food and Drug Administration ("FDA") and other regulatory authority approvals, the regulatory environment and changes in the health policies and structure of various countries, acceptance and demand for new pharmaceutical products and new therapies, uncertainties regarding market acceptance of innovative products newly launched, currently being sold or in development, the impact of restructuring of clients, reliance on strategic alliances, exposure to product liability claims, dependence on patent and other protections for innovative products, fluctuations in currency, exchange and interest rates, operating results and other factors that are discussed in Teva's Annual Report on Form 20-F and its other filings with the U.S. Securities and Exchange Commission ("SEC"). Forward-looking statements speak only as of the date on which they are made, and the Company undertakes no obligation to update publicly or revise any forward-looking statement, whether as a result of new information, future developments or otherwise.